Year All202320222021202020192018201720162015 Poseida Therapeutics to Present at Two Upcoming Investor Conferences September 5, 2023 Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023 August 8, 2023 Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update August 7, 2023 Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy August 7, 2023 Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies July 5, 2023 Poseida Therapeutics to Join Russell 3000® and Russell 2000® Indexes June 26, 2023 Poseida Therapeutics Announces Virtual 2023 Annual Meeting of Stockholders June 1, 2023 Poseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day May 23, 2023 Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis May 22, 2023 Poseida Therapeutics Presents Encouraging Preclinical Data Across its Gene Therapy Programs at the American Society for Gene and Cell Therapy 2023 Annual Meeting May 18, 2023
Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update August 7, 2023
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy August 7, 2023
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies July 5, 2023
Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis May 22, 2023
Poseida Therapeutics Presents Encouraging Preclinical Data Across its Gene Therapy Programs at the American Society for Gene and Cell Therapy 2023 Annual Meeting May 18, 2023
